Indian drug makers Ranbaxy and Wockhardt have been issued a letter by the DCGI to explain deficiencies found at the company’s manufacturing units
Following an import alert by the US FDA, Indian drug maker Wockhardt has now been asked to explain the lapses at the company’s Aurangabad based manufacturing unit that was pulled up by the US drug regulator earlier this year Indian drug makers Ranbaxy and Wockhardt have been issued a letter by the DCGI to explain deficiencies found at the company’s manufacturing units
The Indian Drug Controller General of India (DCGI) has written a letter to the drug maker Wockhardt to explain the deficiencies found at its Aurangabad manufacturing unit. The FDA had issued an import alert to the drug maker earlier this year.
Read more at: http://www.biospectrumasia.com/biospectrum/regulatory/194552/dcgi-wockhardt-ranbaxy-explain-lapses#.UiQ6X6I3CSo
